Movement Alert|Natera rises 4.69% in Pre-Market Trading, Incyte colorectal cancer collaboration and strong revenue outlook support sentiment

Market Focus11-17 19:31

On November 17, Natera rose 4.69% in Pre-Market Trading, trading at $302.0 per share, with turnover of $0.6391 million.

The move follows renewed attention on the company’s clinical collaboration with Incyte for an interventional phase 2 colorectal cancer study, where Signatera is being used as primary and secondary endpoints and is also planned to help guide enrollment, reinforcing its oncology utility.

Supporting context includes third-quarter revenue of $794.0 million, above market expectations, and raised full-year revenue guidance to $3.005 billion to $3.035 billion. However, the company also reported EPS of $(0.42), worse than consensus, while a resale filing covering up to 68,023 shares and recent director share sales had previously weighed on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment